BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 30260261)

  • 1. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
    Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
    Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does autoimmune thyroid disease affect rheumatoid arthritis disease activity or response to methotrexate?
    Waldenlind K; Delcoigne B; Saevarsdottir S; Askling J
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry.
    Karataş A; Pişkin Sağir R; Koca SS; Dalkiliç E; Can G; Pehlivan Y; Yazici A; Inanç N; Cefle A; Ertürk Z; Akar S; Şenel S; Birlik M; Akkoç N; Önen F
    Turk J Med Sci; 2023; 53(5):1321-1329. PubMed ID: 38813042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome.
    Sode J; Vogel U; Bank S; Andersen PS; Thomsen MK; Hetland ML; Locht H; Heegaard NH; Andersen V
    PLoS One; 2014; 9(6):e100361. PubMed ID: 24967817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C).
    Singh N; Madhira V; Hu C; Olex AL; Bergquist T; Fitzgerald KC; Huling JD; Patel RC; Singh JA
    Semin Arthritis Rheum; 2023 Feb; 58():152149. PubMed ID: 36516563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
    Bruijnen S; Tsang-A-Sjoe M; Raterman H; Ramwadhdoebe T; Vugts D; van Dongen G; Huisman M; Hoekstra O; Tak PP; Voskuyl A; van der Laken C
    Arthritis Res Ther; 2016 Nov; 18(1):266. PubMed ID: 27863504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The universal presence of poor prognostic factors based on EULAR recommendations: A real-world study in 1164 Chinese RA patients.
    Gui Y; Zhao J; Xie W; Huang H; Zhang Z
    Joint Bone Spine; 2023 Dec; 90(6):105633. PubMed ID: 37684001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial presentation of early rheumatoid arthritis.
    Weman L; Salo H; Kuusalo L; Huhtakangas J; Kärki J; Vähäsalo P; Backström M; Sokka-Isler T
    PLoS One; 2023; 18(7):e0287707. PubMed ID: 37410796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies.
    Vander Cruyssen B; Durez P; Westhovens R; Kaiser MJ; Hoffman I; De Keyser F;
    Arthritis Res Ther; 2010; 12(5):R169. PubMed ID: 20831776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
    Veeken LD; Opdam MAA; Verhoef LM; Popa C; van Crevel R; den Broeder AA
    Rheumatology (Oxford); 2024 May; 63(5):1246-1250. PubMed ID: 37410085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Dysregulated Central Pain Processing and Response to Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis.
    Heisler AC; Song J; Muhammad LN; Wohlfahrt A; Marder W; Bolster MB; Bingham CO; Clauw DJ; Dunlop DD; Neogi T; Lee YC
    Arthritis Rheumatol; 2020 Dec; 72(12):2017-2024. PubMed ID: 32683800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study.
    Schapink L; den Broeder N; den Broeder AA; Verhoef LM
    Rheumatol Int; 2024 Jan; ():. PubMed ID: 38286887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact.
    Chandramohan P; Jain A; Antony G; Krishnan N; Shenoy P
    Rheumatol Adv Pract; 2021; 5(1):rkaa077. PubMed ID: 33605940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis.
    Franklin J; Lunt M; Bunn D; Symmons D; Silman A
    Ann Rheum Dis; 2007 Mar; 66(3):308-12. PubMed ID: 16984941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and predisposing factors of extra-articular manifestations in contemporary rheumatoid arthritis.
    Ljung L; Jönsson E; Franklin J; Berglin E; Lundquist A; Rantapää-Dahlqvist S
    Eur J Intern Med; 2024 May; ():. PubMed ID: 38705755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Widespread pain and pain intensity in patients with early rheumatoid arthritis. A cross-sectional comparison between smokers and non-smokers.
    Karlsson ML; Elkan AC; Hafström I
    Nurs Open; 2019 Jul; 6(3):942-947. PubMed ID: 31367417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking: keeping the joint alight.
    Mouyis M; Abraham S
    Clin Med (Lond); 2012 Aug; 12(4):399-400. PubMed ID: 22930897
    [No Abstract]   [Full Text] [Related]  

  • 18. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
    Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
    Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.
    Vogelzang EH; Hebing RCF; Nurmohamed MT; van Kuijk AWR; Kruijff JWF; l'Ami MJ; Krieckaert CLM; Wolbink G
    PLoS One; 2018; 13(10):e0205125. PubMed ID: 30300358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept.
    Picchianti-Diamanti A; Panebianco C; Salemi S; Sorgi ML; Di Rosa R; Tropea A; Sgrulletti M; Salerno G; Terracciano F; D'Amelio R; Laganà B; Pazienza V
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.